• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Fahs L Reade bought $299,200 worth of shares (20,000 units at $14.96), increasing direct ownership by 3% to 633,097 units (SEC Form 4)

    5/14/24 8:01:46 AM ET
    $EYE
    Ophthalmic Goods
    Health Care
    Get the next $EYE alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    FAHS L READE

    (Last) (First) (Middle)
    C/O NATIONAL VISION HOLDINGS, INC.,
    2435 COMMERCE AVENUE, BLDG. 2200

    (Street)
    DULUTH GA 30096-4980

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    National Vision Holdings, Inc. [ EYE ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Executive Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    05/13/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 05/13/2024 P 20,000 A $14.96(1) 633,097 D
    Common Stock 363,430 I Held by Trust
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Price represents the weighted average price. The shares were purchased pursuant to a single order in multiple transactions at prices ranging from $14.925 to $15.00. Upon request by the SEC staff, the issuer or a security holder of the issuer, the reporting person will provide full information regarding the number of shares purchased at each separate price.
    Remarks:
    /s/ Jared Brandman, as Attorney-in-Fact 05/14/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $EYE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EYE

    DatePrice TargetRatingAnalyst
    5/9/2025$21.00Neutral → Buy
    Citigroup
    5/7/2025Underperform → Buy
    BofA Securities
    10/17/2023$25.00 → $16.00Buy → Neutral
    Goldman
    7/27/2023$28.00 → $22.00Buy → Neutral
    Citigroup
    7/27/2023$30.00 → $21.00Overweight → Equal Weight
    Wells Fargo
    5/2/2023Overweight → Equal Weight
    Barclays
    3/31/2023$23.00Hold → Buy
    Loop Capital
    1/17/2023Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $EYE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • National Vision upgraded by Citigroup with a new price target

      Citigroup upgraded National Vision from Neutral to Buy and set a new price target of $21.00

      5/9/25 8:39:42 AM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • National Vision upgraded by BofA Securities

      BofA Securities upgraded National Vision from Underperform to Buy

      5/7/25 2:46:43 PM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • National Vision downgraded by Goldman with a new price target

      Goldman downgraded National Vision from Buy to Neutral and set a new price target of $16.00 from $25.00 previously

      10/17/23 7:19:16 AM ET
      $EYE
      Ophthalmic Goods
      Health Care

    $EYE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Zulla Caitlin was granted 10,870 units of Restricted Stock Units, increasing direct ownership by 99% to 21,880 units (SEC Form 4)

      4 - National Vision Holdings, Inc. (0001710155) (Issuer)

      6/23/25 4:40:50 PM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • Director Ofarrell Susan C was granted 9,674 shares, increasing direct ownership by 76% to 22,333 units (SEC Form 4)

      4 - National Vision Holdings, Inc. (0001710155) (Issuer)

      6/23/25 4:39:21 PM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • Director Nicholson Michael J was granted 7,392 units of Restricted Stock Units, increasing direct ownership by 222% to 10,719 units (SEC Form 4)

      4 - National Vision Holdings, Inc. (0001710155) (Issuer)

      6/23/25 4:38:28 PM ET
      $EYE
      Ophthalmic Goods
      Health Care

    $EYE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • National Vision Announces Participation in William Blair Growth Stock Conference

      National Vision Holdings, Inc. (NASDAQ:EYE) ("National Vision" or the "Company") today announced that the Company is scheduled to present at the 45th annual William Blair Growth Stock Conference on Wednesday, June 4, 2025, at 9:20 a.m. Central Time. A live webcast of the presentation can be accessed in the "Investors" section of the Company's website at www.nationalvision.com/investors. The webcast will be archived and available on the website shortly after the event. About National Vision Holdings, Inc. National Vision Holdings, Inc. (NASDAQ:EYE) is one of the largest optical retail companies in the United States with over 1,200 stores in 38 states and Puerto Rico. With a mission of hel

      5/21/25 4:05:00 PM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • National Vision Announces Settlement of 2025 Convertible Senior Notes

      National Vision Holdings, Inc. (NASDAQ:EYE) ("National Vision" or the "Company") today announced the settlement of the remaining $84.8 million aggregate principal amount of 2.5% unsecured convertible senior notes due May 15, 2025 (the "2025 Convertible Notes"). The settlement was made with $59.8 million from cash on hand and the remaining borrowed under the Company's revolving credit facility. Chris Laden, Chief Financial Officer of National Vision, said, "Our strong cash generation and solid balance sheet support our ongoing approach to a balanced capital allocation strategy, which has included the opportunistic repurchases and the final settlement of our convertible notes. As we look ahe

      5/15/25 4:05:00 PM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • National Vision Holdings, Inc. Reports First Quarter 2025 Financial Results

      Successful Execution of New Transformation Initiatives and Cost Reduction Actions Delivered Strong First Quarter First quarter 2025 highlights compared to Q1 2024: Net revenue from continuing operations of $510.3 million, an increase of 5.7% Comparable store sales growth of 4.1% and Adjusted Comparable Store Sales Growth of 5.5% represented the 9th consecutive quarter of positive growth Income from continuing operations of $14.2 million, Diluted EPS from continuing operations of $0.18 Adjusted Operating Income from continuing operations of $41.3 million Adjusted Diluted EPS from continuing operations of $0.34 Raises fiscal 2025 outlook National Vision Holdings, Inc. (NASDAQ:E

      5/7/25 6:00:00 AM ET
      $EYE
      Ophthalmic Goods
      Health Care

    $EYE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Peeler D Randolph bought $264,200 worth of shares (25,000 units at $10.57) (SEC Form 4)

      4 - National Vision Holdings, Inc. (0001710155) (Issuer)

      8/14/24 4:27:52 PM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • Director Hepner Virginia A bought $10,365 worth of shares (1,000 units at $10.37), increasing direct ownership by 3% to 36,635 units (SEC Form 4)

      4 - National Vision Holdings, Inc. (0001710155) (Issuer)

      8/14/24 4:26:51 PM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • Fahs L Reade bought $299,200 worth of shares (20,000 units at $14.96), increasing direct ownership by 3% to 633,097 units (SEC Form 4)

      4 - National Vision Holdings, Inc. (0001710155) (Issuer)

      5/14/24 8:01:46 AM ET
      $EYE
      Ophthalmic Goods
      Health Care